Con: Biomarkers in glomerular diseases: putting the cart before the wheel? - Wikidata - awgldk - TriplyDB

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

http://www.wikidata.org/entity/Q53497916

about

Novel Biomarkers for Renal Diseases? None for the Moment (but One).What are we missing in the clinical trials of focal segmental glomerulosclerosis?Moderator's view: Biomarkers in glomerular diseases--translated into patient care or lost in translation?

P2860

Q38763898-3CB273EC-796A-4F06-AD8C-642598535193 Q39229298-79BE8614-C690-452E-B674-6C6065447A5C Q53499269-7C5B282B-5E2B-4642-BE67-521BA491F26F

P2860

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

http://www.wikidata.org/entity/Q53497916

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@en

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@nl

type

label

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@en

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@nl

prefLabel

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@en

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@nl

P1433

Q53497916-A8F74158-EDEF-41F3-8F84-A07D357F604D

P1476

Q53497916-35014F4D-53A6-4D9D-9848-8F4E62B9996F

P2093

Q53497916-ADB7CAE0-790E-4456-9D6C-AB60A51E4B28

P2860

Q53497916-09D9E5B3-DA49-4BF2-AF45-951365BC2FEE

Q53497916-0A969C82-1C1C-4370-861C-4210DDB54754

Q53497916-0E4DB3EA-9F3B-4CCE-8821-2F758C0B4AC8

Q53497916-116D60E4-6AA6-414C-8DAA-F8424C4577A3

Q53497916-129F2C1E-EF38-4C6E-BDDB-1FA9B52FABF2

Q53497916-13AB734D-E4FE-4271-AC2C-85B7807F73FD

Q53497916-1C071D33-C9D4-4B16-B6D7-A1DED733D6B8

Q53497916-2273C64C-E1A2-4D30-9D03-F48A78341A49

Q53497916-23A337B0-5DF7-417C-9628-EEA56631B8AD

Q53497916-2B8357A9-127E-41A8-B56E-234D8B3F97E7

P304

Q53497916-D7EDC10A-F46B-4D38-9F20-3CB3F7AC682C

P31

Q53497916-BAC313BF-80E7-49FA-8D85-B2901B7E669D

P356

Q53497916-1F565A22-5991-4302-A9A9-FC806C40490A

P407

Q53497916-CBE5AEFC-C4FF-4131-AF6F-48838E060147

P433

Q53497916-ABC072A4-BC40-487C-9E0E-0BEB1F584F46

P478

Q53497916-F889C9A4-430B-4D8A-B277-4DEAC0900522

P50

Q53497916-864D2FEA-CD4A-4742-A62D-704945537AFD

P577

Q53497916-36B5CC19-1C3A-4485-AB2E-4836E4F35F14

P5875

Q53497916-DE9E8F90-1F0E-429E-979F-18FF6FE68D90

P698

Q53497916-A223F491-D7CD-4443-981E-C36F00581840

P356

P1433

Nephrology Dialysis Transplantation

P1476

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

@en

P2093

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

P2860

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

Treatment of primary FSGS in adults

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI.

Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry.

Identification of a urinary proteomic signature for lupus nephritis in children.

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

P304

885-890

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFV107

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277083449

http://www.w3.org/2001/XMLSchema#string

P698

25994657

http://www.w3.org/2001/XMLSchema#string